Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

1.150 -0.040 (-3.36%)
Streaming Delayed Price Updated: 11:08 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,876
Open 1.200
Bid (Size) 1.150 (11,700)
Ask (Size) 1.180 (400)
Prev. Close 1.190
Today's Range 1.150 - 1.200
52wk Range 1.140 - 8.940
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and... 
From Medicus Pharma Ltd
Via GlobeNewswire

Performance

YTD
-28.1%
-28.1%
1 Month
-28.1%
-28.1%
3 Month
-50.9%
-50.9%
6 Month
-51.7%
-51.7%
1 Year
-54.9%
-54.9%

More News

Read More
News headline image
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Via ACCESS Newswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch
Via AB Newswire
News headline image
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
From Medicus Pharma Ltd.
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
From Medicus Pharma
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries
Via AB Newswire
Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)
Via AB Newswire
News headline image
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
From Medicus Pharma
Via GlobeNewswire
4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
Via AB Newswire
News headline image
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)
Via AB Newswire
News headline image
Three Biotech Companies Redefining Value Creation Through Dual Strategies
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
Via ACCESS Newswire
Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
Via AB Newswire

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?
Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.
What exchange does Medicus Pharma Ltd. - Common Stock trade on?
Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?
The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market
What is the current price of Medicus Pharma Ltd. - Common Stock?
The current price of Medicus Pharma Ltd. - Common Stock is 1.150
When was Medicus Pharma Ltd. - Common Stock last traded?
The last trade of Medicus Pharma Ltd. - Common Stock was at 02/03/26 11:08 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.